Waist circumference, not the metabolic syndrome, predicts glucose deterioration in type 2 diabetes

Obesity

Volumn 16, Issue 4, 2008, Pages 869-874

  Blaha, Michael J ^a   Gebretsadik, Tebeb ^b   Shintani, Ayumi ^b   Elasy, Tom A ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL FAT; ADULT; AGED; ARTICLE; BODY MASS; DISEASE COURSE; FEMALE; GLUCOSE INTOLERANCE; HUMAN; HYPERGLYCEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR; WAIST HIP RATIO;

ABDOMINAL FAT; ADULT; AGED; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPERGLYCEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RISK FACTORS; WAIST-HIP RATIO;

EID: 41549164026     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2008.12     Document Type: Article

References (38)

1. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004;53:1195-1200.
2. Lorenzo C., Okoloise M, Williams K, Stern MP, Haffner SM. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003;26:3153-3159.
3. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs. Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005;165:2644-2650.
4. Hanley AJ, Karter AJ, Williams K et al. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Circulation 2005;112:3713-3721.
5. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002;156:1070-1077.
6. Marchesini G, Forlani G, Cerrelli F et al. WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. Diabet Med 2004:21:383-387.
7. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
8. Bonora E, Targher G, Formentini G et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med 2004;21:52-58.
9. Athyros VG, Mikhailidis DP, Papageorgiou AA et al. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin 2004;20:1691-1701.
10. Guzder R, Gatling W, Mullee M, Byrne C. Impact of metabolic syndrome criteria on cardiovascular disease risk In people with newly diagnosed type 2 diabetes. Diabetobgia 2006;49:49-55.
11. Isomaa B, Henricsson M, Almgren P et al. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001;44:1148-1154.
12. Costa LA, Canani LH, Lisboa HR, Tres GS, Gross JL Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. Diabet Med 2004;21:252-255.
13. Bruno G, Merletti F, Biggeri A et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004:27:2689-2694.
14. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-2304.
15. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
16. Nathan DM. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. W Engl J Med 2002;347:1342-1349.
17. Graber AL, Davidson P, Brown AW, McRae JR, Woolridge K. Dropout and relapse during diabetes care. Diabetes Care 1992;15:1477-1483.
18. Hulzinga MM, Shintani A, Michon S et al. A randomized controlled trial to prevent glycemic relapse in longitudinal diabetes care: Study protocol (NCT00362193). Implement Sci 2006;1:24.
19. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002;106:3143-3421.
20. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome. Circulation 2005;112:2735-2752.
21. National Institutes of Health, National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Obes Res 1998;6(Suppl 2):S51-S210.
22. Radloff L, Teri L. Use of the CES-D with older adults. Clin Gerontol 1977;5:119-136.
23. Goldstein DE, Little RR, Lorenz RA et al. Tests of glycemia in Diabetes. Diabetes Care 2004;27(Suppl 1):S91-S93.
24. Energy and Protein Requirements. Report of a Join FAO/WHO/UNU Expert Consultation. Technical Report Series, 1985:724. Geneva, WHO.
25. Perduzzi P, Concato J, Kemper E, Holford T, Feinstein A. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373-1379.
26. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
27. Joffe M, Rausenbaum R Invited commentary: propensity scores. Am J Epidemiol 1999;150:327-333.
28. Elasy TA, Graber AL, Wolff K, Brown A, Shintani A. Glycemic relapse after an intensive outpatient intervention for type 2 diabetes. Diabetes Care 2003;26:1645-1646.
29. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem 2005;51:931-938.
30. Reaven G. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
31. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004;33:283-303.
32. Liao Y, Kwon S, Shaughnessy S et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care 2004;27:978-983.
33. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139:802-809.
34. Blaha MJ, Elasy TA. Clinical Use of the Metabolic Syndrome: Why the Confusion? Clin Diabetes 2006;24:125-131.
35. Sierra-Johnson J, Johnson BD, Allison TG, Bailey KB, Schwartz GL, Turner ST. Correspondence between the adult treatment panel III criteria for metabolic syndrome and insulin resistance. Diabetes Care 2006;29:668-672.
36. Rattarasarn C. Physiological and pathophysiological regulation of regional adipose tissue in the development of insulin resistance and type 2 diabetes. Acta Physilogica 2006;186:87-101.
37. Reaven G. All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals. Diab Vase Dis Res 2005;2:105-112.
38. Farin HM, Abbasi F, Reaven GM. Body mass index and waist circumference correlate to the same degree with insulin-mediated glucose uptake. Metab Clin Exp 2005;54:1323-1328.